Literature DB >> 28533321

Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure).

Kishan S Parikh1, Steven J Lippmann1, Melissa Greiner1, Paul A Heidenreich1, Clyde W Yancy1, Gregg C Fonarow1, Adrian F Hernandez2.   

Abstract

Entities:  

Keywords:  drugs; heart failure

Mesh：

Substances：

Year:  2017        PMID： 28533321      PMCID： PMC5475261          DOI： 10.1161/CIRCULATIONAHA.117.027773

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

1.  Overview of the American Heart Association "Get with the Guidelines" programs: coronary heart disease, stroke, and heart failure.

Authors:  Yuling Hong; Kenneth A LaBresh
Journal:  Crit Pathw Cardiol       Date:  2006-12

2.  Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.

Authors:  Scott D Solomon; Brian Claggett; Akshay S Desai; Milton Packer; Michael Zile; Karl Swedberg; Jean L Rouleau; Victor C Shi; Randall C Starling; Ömer Kozan; Andrej Dukat; Martin P Lefkowitz; John J V McMurray
Journal:  Circ Heart Fail       Date:  2016-03       Impact factor: 8.790

3.  Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization.

Authors:  Akshay S Desai; Brian L Claggett; Milton Packer; Michael R Zile; Jean L Rouleau; Karl Swedberg; Victor Shi; Martin Lefkowitz; Randall Starling; John Teerlink; John J V McMurray; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2016-07-19       Impact factor: 24.094

4.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

5.  Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.

Authors:  Joanne Simpson; Pardeep S Jhund; Jose Silva Cardoso; Felipe Martinez; Arend Mosterd; Felix Ramires; Adel R Rizkala; Michele Senni; Iain Squire; Jianjian Gong; Martin P Lefkowitz; Victor C Shi; Akshay S Desai; Jean L Rouleau; Karl Swedberg; Michael R Zile; John J V McMurray; Milton Packer; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2015-11-10       Impact factor: 24.094
  5 in total
  11 in total

1.  Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure.

Authors:  Andrew Sumarsono; Muthiah Vaduganathan; Ezimamaka Ajufo; Ann Marie Navar; Gregg C Fonarow; Sandeep R Das; Ambarish Pandey
Journal:  JAMA Cardiol       Date:  2020-03-01       Impact factor: 14.676

Review 2.  Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials.

Authors:  Chaudhry M S Sarwar; Muthiah Vaduganathan; Javed Butler
Journal:  Curr Heart Fail Rep       Date:  2017-08

3.  Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF.

Authors:  Stephen J Greene; Adam D DeVore; Shubin Sheng; Gregg C Fonarow; Javed Butler; Robert M Califf; Adrian F Hernandez; Roland A Matsouaka; Ayman Samman Tahhan; Kevin L Thomas; Muthiah Vaduganathan; Clyde W Yancy; Eric D Peterson; Christopher M O'Connor; Robert J Mentz
Journal:  JACC Heart Fail       Date:  2019-10-09       Impact factor: 12.035

4.  Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry.

Authors:  Muthiah Vaduganathan; Stephen J Greene; Shuaiqi Zhang; Maria Grau-Sepulveda; Adam D DeVore; Javed Butler; Paul A Heidenreich; Joanna C Huang; Michelle M Kittleson; Karen E Joynt Maddox; James J McDermott; Anjali Tiku Owens; Pamela N Peterson; Scott D Solomon; Orly Vardeny; Clyde W Yancy; Gregg C Fonarow
Journal:  JAMA Cardiol       Date:  2020-11-13       Impact factor: 14.676

5.  SAcubitril/valsartan versus ramipril in patients with ST-segment Elevation Myocardial Infarction and cardiogenic SHOCK (SAVE-SHOCK): a pilot randomized controlled trial.

Authors:  Ahmed Rezq; Marwan Saad; Mostafa El Nozahi
Journal:  Am J Cardiovasc Dis       Date:  2021-12-15

Review 6.  Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.

Authors:  Srikanth Yandrapalli; Gabriela Andries; Medha Biswas; Sahil Khera
Journal:  Vasc Health Risk Manag       Date:  2017-10-05

7.  "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.

Authors:  Joanne Simpson; L Benson; P S Jhund; U Dahlström; J J V McMurray; L H Lund
Journal:  Cardiovasc Drugs Ther       Date:  2019-06       Impact factor: 3.727

8.  Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.

Authors:  Nancy M Albert; Jason P Swindle; Erin K Buysman; Chunlan Chang
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

9.  Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.

Authors:  Marat Fudim; Sabina Sayeed; Haolin Xu; Roland A Matsouaka; Paul A Heidenreich; Eric J Velazquez; Clyde W Yancy; Gregg C Fonarow; Adrian F Hernandez; Adam D DeVore
Journal:  Circ Heart Fail       Date:  2020-04-06       Impact factor: 8.790

10.  Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.

Authors:  Adam D DeVore; Xiaojuan Mi; Laine Thomas; Puza P Sharma; Nancy M Albert; Javed Butler; Adrian F Hernandez; J Herbert Patterson; John A Spertus; Fredonia B Williams; Carol I Duffy; Kevin McCague; Gregg C Fonarow
Journal:  J Am Heart Assoc       Date:  2018-06-12       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.